Pfizer (NYSE:PFE) Shares Down 2.3% – Here’s What Happened

Pfizer Inc. (NYSE:PFE) traded down 2.3% during mid-day trading on Tuesday. The company traded as low as $29.89 and last traded at $29.9750. 52,648,660 shares were traded during trading, an increase of 33% from the average session volume of 39,723,945 shares. The stock had previously closed at $30.67.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported adjusted earnings of $0.87 per share and revenue of $16.58 billion, exceeding analyst estimates. It raised its 2026 revenue outlook to $62 billion–$64 billion, citing strong performance and execution. Reuters: Pfizer raises 2026 forecast
• Positive Sentiment: Growth in newer and acquired medicines helped offset weakness elsewhere: launched products grew 32%, with Eliquis, Padcev and Lorbrena among the drivers. This supports Pfizer’s effort to build growth beyond its pandemic-era products. Blockonomi: Pfizer Q3 revenue and launched products
• Neutral Sentiment: Pfizer appointed longtime company finance executive Cecile Guegan as CFO, effective November 1. The appointment offers continuity, though the reports provided no expected financial impact. CNBC: Pfizer hikes outlook and names new CFO
• Negative Sentiment: Revenue was essentially flat year over year as COVID product sales continued to contract: Paxlovid revenue fell 63% and Comirnaty sales dropped 29%. Those declines may temper confidence in the durability of Pfizer’s growth, despite the stronger non-COVID portfolio. The Motley Fool: Eliquis gains and COVID sales declines

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. JPMorgan Chase & Co. boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Five research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.65.

Pfizer Price Performance

The firm has a market cap of $170.85 billion, a P/E ratio of 39.44, a PEG ratio of 2.00 and a beta of 0.32. The company has a fifty day moving average price of $28.60 and a two-hundred day moving average price of $26.82. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the company earned $0.87 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 5.7%. Pfizer’s payout ratio is currently 226.32%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently added to or reduced their stakes in PFE. BlackRock Inc. lifted its position in shares of Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares in the last quarter. State Street Corp increased its stake in shares of Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Pfizer by 11.1% during the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock valued at $1,512,948,000 after acquiring an additional 5,364,929 shares during the period. Bank of America Corp DE purchased a new stake in Pfizer during the 2nd quarter worth about $1,049,602,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Pfizer by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after buying an additional 293,029 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.